Our report shows that LMTK2 is an essential negative regulator of AR transcriptional activity and knocking down its expression in prostate cancer cells leads to significant increase in the AR activity and also an increase in tumorogenecity and cell viability. The gene discussed is AR; the disease is prostate carcinoma.